GC Cell Signs MOU with KALBE Affiliate

 

GC Cell, a leading pioneer in cell and gene therapy, is excited to announce a new strategic partnership with Bifarma, a prominent player in stem cell therapy in Indonesia. Bifarma, a subsidiary of PT Kalbe Farma Tbk, Southeast Asia's top pharmaceutical company, brings extensive expertise in R&D, GMP-compliant manufacturing, and the commercialization of cell therapies.

This partnership is a major milestone for GC Cell as it allows them to enter the Indonesian market and expand their presence in the innovative cell therapy sector. One of the key objectives is to introduce 'Immuncell-LC', the only approved autologous T-cell therapy for liver cancer surgery in Korea, to the Indonesian market. Additionally, the partnership includes discussions on technology transfer and collaboration in developing NK cell therapy pipelines.

In addition to this exciting partnership, GC Cell has recently unveiled its Blueprint 2.0 strategy, which focuses on future growth drivers. A crucial aspect of this strategy is the global market entry of their proprietary cell therapy products, including Immuncell-LC, Korea's groundbreaking cell therapy. They also aim to establish a strong foundation for NK cell therapy pipelines across the Asia-Pacific region.

Indonesia, with its large population, rapid growth rate, and the rise of universal healthcare, presents a promising market for autologous cell therapies. These therapies are becoming more accessible through medical procedures supported by extensive clinical data, similar to those in Japan. By partnering with Bifarma and leveraging the extensive infrastructure and hospital network of the Kalbe Group, GC Cell expects to expedite the launch of Immuncell-LC beyond Korea.

More Information : https://www.techdogs.com/tech-news/pr-newswire/gc-cell-signs-an-mou-with-pt-bifarma-adiluhung-an-affiliate-of-kalbe-group